C linical and epidemiological studies show a robust, inverse association of high-density lipoprotein cholesterol (HDL-C) levels with cardiovascular disease (CVD) risk. 1 In mouse models of atherosclerosis, HDL's ability to remove cholesterol from macrophages in the artery wall is a key cardioprotective function. 2, 3 A well-established pathway involves apolipoprotein A-I (apoA-I), HDL's major protein. 4 Lipid-free apoA-I promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1 (ABCA1), a membraneassociated transporter. 5, 6 Humans lacking ABCA1 have Tangier disease, 7 which is characterized by low levels of HDL-C and accumulation of cholesterol-loaded macrophage in many different tissues. 8, 9 Ablation of ABCA1 in mouse myeloid cells promotes atherosclerosis in hypercholesterolemic mice without affecting HDL-C levels, 10, 11 indicating that cholesterol efflux by the ABCA1 pathway is of central importance in the cardioprotective effects of HDL. Inflammation impairs macrophage sterol efflux in animal models, rendering HDL dysfunctional. [12] [13] [14] However, the underlying mechanisms and relevance of these findings to human atherosclerosis remain unclear.
human atherosclerotic tissue. 14, 17 The enzyme uses H 2 O 2 and chloride ion to produce hypochlorous acid (HOCl), which converts tyrosine to 3-chlorotyrosine. [18] [19] [20] It also oxidizes methionine residues. 21 When lipid-free apoA-I is oxidized by myeloperoxidase in vitro, its ability to remove excess cellular cholesterol by the ABCA1 pathway is decreased. [22] [23] [24] Moreover, in vitro studies with a mutated form of apoA-I and biochemical studies with methionine sulfoxide [Met(O)] reductase suggest that chlorination of tyrosine 192 in concert with oxidation of methionine impairs ABCA1 transport activity. 25 Oxidation of methionine in apoA-I also impairs its ability to activate lecithin-cholesterol acyltransferase, 26 which plays a key role in maturation of HDL. Elevated levels of chlorotyrosine have been detected in HDL isolated from subjects with coronary disease, 22, 24 and tyrosine 192 is the major chlorination site in apoA-I of HDL isolated from human atherosclerotic lesions. 27 These observations suggest that oxidation might impair human HDL's cardioprotective functions, such as cholesterol clearance from macrophages in the artery wall.
Inflammation and metabolic disorders have been proposed to convert HDL to a dysfunctional form lacking antiatherogenic properties. 12, 13, 28 Consistent with this proposal, the ability of serum HDL to promote sterol efflux from cultured macrophages varies markedly, despite similar levels of HDL-C and apoA-I. 29 Therefore, HDL-C is not necessarily the major determinant of HDL's macrophage sterol efflux capacity. One proposed factor is HDL's activity with the ABCA1 pathway. 29 Importantly, the efflux capacity of serum HDL with cultured macrophages associated strongly and negatively with coronary artery disease (CAD) status, 30 and that association was independent of HDL-C and apoA-I levels. Taken together, these observations suggest that serum HDL's capacity to promote sterol efflux from macrophages reflects its functionality, raising the possibility that this function of HDL provides insight into the relationship between HDL biology and CAD risk.
The factors that control the efflux capacity of serum HDL remain poorly understood. In the current study, we isolated HDL from control subjects and subjects with stable CAD 31 or acute coronary syndrome (ACS) 32 and used tandem mass spectrometry (MS) to explore the relationship between site-specific oxidation of apoA-I and the protein's ability to promote cholesterol efflux by the ABCA1 pathway. We show that levels of chlorinated and oxidized apoA-I are elevated in subjects with CAD and ACS, and that they correlate inversely with HDL's cholesterol efflux capacity. Moreover, HDL from subjects with CAD and ACS was less able to accept sterol from cells expressing ABCA1 compared with HDL from control subjects. Thus, myeloperoxidase may help generate dysfunctional HDL in humans.
Methods

Subjects
Plasma samples were collected prospectively over 10 months from 3 groups of subjects at the University of Washington: control subjects (n=20), subjects with stable CAD (n=20), and subjects with ACS (n=20). The control subjects, who were recruited by advertisement, had no clinical history of CVD, no family history of premature CAD, and were not receiving lipid-lowering therapy. Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months. Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus. All subjects provided signed informed consent, and all protocols were approved by the University of Washington Institutional Review Board.
Plasma Levels of Lipids, High-Sensitivity C-Reactive Protein, and Myeloperoxidase
Lipid profiles and high-sensitivity C-reactive protein (hs-CRP) were determined by the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington. All lipid analyses were standardized using the Centers for Disease Control and Prevention Reference Methods. Myeloperoxidase levels in plasma were measured by the Cleveland Heart Laboratory (Cleveland, OH).
HDL Isolation From Plasma
Blood was collected from overnight-fasted subjects into ice-cold tubes containing EDTA (6 mmol/L final concentration). To protect methionine residues from oxidation, 33 plasma was prepared immediately by centrifugation (2500g for 15 minutes) and frozen at −80°C until analysis. HDL (density, 1.063-1.210 g/mL) was isolated by sequential ultracentrifugation from freshly thawed plasma, 27 using buffers supplemented with 100 μmol/L diethylenetriaminepentaacetic acid, 100 μmol/L butylated hydroxytoluene, and a protease inhibitor mixture (Sigma, St Louis, MO). All studies were performed on samples that had been stored for <12 months, and freshly prepared methionine (10 mmol/L final) was added to each sample before work-up for MS analysis.
Isotope-Labeled ApoA-I
15 N-labeled apoA-I was prepared by growing bacteria that stably express human apoA-I in minimal medium supplemented with [
15 N]H 4 Cl.
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Mass Spectrometric Analysis With Selected Reaction Monitoring
The protein concentration of HDL was determined using the Lowry assay (BioRad), with albumin as the standard. After the addition of freshly prepared methionine (10 mmol/L final concentration), proteins were reduced with dithiothreitol and alkylated with iodoacetamide. 27 After digestion of apoA-I with sequencing-grade modified trypsin (Promega) or endoproteinase Glu-C (from Staphylococcus aureus V8; Roche Applied Science), site-specific oxidation of apoA-I was quantified by selected reaction monitoring, a 27, 35 in peptide digests of HDL with a nano-LC-MS/MS as described. 27 Additional details are provided in the Online Data Supplement.
Ex Vivo Oxidation of HDL
Preliminary studies demonstrated that tyrosine chlorination was negligible in recombinant apoA-I and reconstituted HDL analyzed by tandem MS, indicating that sample work-up and MS analysis did not contribute significantly to ex vivo oxidation. However, when reconstituted HDL disks made from apoA-I and phospholipid-containing linoleic acid (which is highly susceptible to oxidation) were isolated by ultracentrifugation, oxidation of methionine 86 and methionine 112 in apoA-I increased significantly (Online Figure I) . In contrast, there was no evidence of increased oxidation of methionine 148 (Online Figure I) . Moreover, there was no additional oxidation of methionine 148 in 15 N-apoA-I when reconstituted HDL (made from 15 N-apoA-I) was incubated in plasma and then isolated by ultracentrifugation (Online Figure II) . The addition to plasma of azide (10 mmol/L), a potent inhibitor of myeloperoxidase, did not affect methionine oxidation or tyrosine chlorination of HDL or reconstituted HDL (Online Figures II and III) . These data suggest that lipid oxidation products, but not plasma myeloperoxidase or other heme proteins, can contribute to ex vivo oxidation of methionine 86 and methionine 112, but not methionine 148, as previously described.
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ABCA1 Efflux Capacity of Serum HDL and In Vitro Oxidized HDL
Serum was derived from plasma by adding calcium. 29 Polyethylene glycol was then used to precipitate lipoproteins containing apolipoprotein B, and the supernatant was centrifuged to generate serum HDL. ABCA1-specific sterol efflux to serum HDL was quantified using baby hamster kidney cells expressing mifepristone-inducible human ABCA1. 30, 37 HDL isolated by ultracentrifugation was oxidized with HOCl and reduced with pilB as described. 25, 26 ABCA1-specific efflux capacity of oxidized and reduced HDL was measured as previously described. 25, 37 Additional details are provided in the Online Data Supplement.
Statistical Analysis
Continuous variables are presented as mean and SD, and categorical variables as frequencies and percentages. Because levels of chlorotyrosine 192 and Met(O) 148 exhibited a nonnormal distribution in our study population, we used logarithmic transformation in all analyses. Linear regression analysis with continuous variables used Pearson coefficient. Multiple logistic regression was used to estimate the association between 3-chlorotyrosine 192, Met(O) 148, cholesterol efflux capacity, and CVD status after adjustment for HDL-C levels. Odds ratios are reported for 1 SD change for continuous variables. Significant P values were α<0.05 on 2-tailed analysis. Statistical analyses were performed with SPSS (Windows version 19; Chicago, IL) or OriginPro (version 8.6; Origin Laboratory, Northampton, MA).
Results
The clinical characteristics and lipid values of subjects are shown in the Table. Analysis with 1-way ANOVA indicated a significant difference in HDL-C levels among the groups (P=0.0003). Further analysis with Fisher least significance difference (LSD) test demonstrated that the groups with stable CAD (42±11 mg/dL; n=20) and ACS (47±17 mg/dL; n=20) had significantly lower HDL-C levels (P=0.0001 and 0.003, respectively) compared with the healthy control group (61±16 mg/dL; n=20). Low-density lipoprotein cholesterol (LDL-C) levels were similar in the control and ACS groups but lower in the CAD group (P=0.009; Fisher LSD test; CAD versus control), likely because all subjects with CAD were on statin therapy. Plasma levels of myeloperoxidase were similar in the control and CAD groups, but higher in the ACS group. However, the differences in myeloperoxidase levels between the groups were not significant by 1-way ANOVA. In contrast, the ACS and CAD groups had significantly higher levels of hs-CRP compared with the control group (P=0.02 and <0.0001, respectively; Fisher LSD test).
Subjects With Stable CAD and ACS Have Elevated Levels of Chlorinated and Oxidized ApoA-I
To quantify oxidation sites in HDL isolated by ultracentrifugation from human plasma of controls and subjects with CAD and ACS, we supplemented the HDL with 15 N-apoA-I chlorinated with reagent HOCl. Levels of 3-chlorotyrosine and Met(O) in peptide digests were quantified by tandem MS with selected reaction monitoring and isotope dilution. 27, 35 This sensitive and quantitative approach detected all 7 peptides that contain tyrosine, all 3 peptides that contain methionine, and the corresponding chlorinated and oxidized products.
Chlorinated peptides were readily detectable in the proteolytic digests of apoA-I prepared from HDL isolated from human plasma ( Figure 1A ). Moreover, we identified tyrosine 192 as the major chlorination site in apoA-I of HDL isolated from both the diseased and control subjects (P<0.0001 versus tyrosine 18; Student t test), as previously demonstrated for HDL isolated from human atherosclerotic lesions. 27 The average level (mean±SD) of 3-chlorotyrosine 192 in all the subjects was 62±26 μmol/mol tyrosine. Tyrosine 18 was the second major site of chlorination, with an average level of 29±11 μmol/mol tyrosine. Lower levels of 3-chlorotyrosine (<10 μmol/mol tyrosine) were detected at the other 5 tyrosine residues.
To determine whether the healthy and diseased groups had different levels of 3-chlorotyrosine in the apoA-I from their plasma HDL, we calculated the overall levels of tyrosine chlorination for all 7 tyrosine residues. The total level of protein-bound 3-chlorotyrosine in the control group was 14±2.5 μmol/mol tyrosine (n=20). In the CAD (n=20) and ACS (n=20) groups, it was 17±3.9 and 20±8.2 μmol/mol tyrosine, respectively. Analysis by 1-way ANOVA indicated that total chlorotyrosine levels differed among the groups (P=0.009). Total levels of 3-chlorotyrosine in apoA-I of HDL from the subjects with CAD or ACS were significantly higher than in healthy control subjects (P=0.04 and 0.002; Fisher LSD test). Levels of 3-chlorotyrosine ranged from 10 to 19 μmol/mol tyrosine in the control group, 11 to 24 μmol/mol tyrosine in the CAD group, and 10 to 41 μmol/mol tyrosine in the ACS group.
Subjects With CAD and ACS Have Elevated Levels of Chlorinated Tyrosine 192 and Oxidized Methionine 148
Because tyrosine 192 was the major chlorination site in apoA-I of HDL isolated from human plasma, we determined whether subjects with CAD or ACS had higher levels of that chlorinated residue ( Figure 1B) . The average level of 3-chlorotyrosine 192 in the control group was 50±8.5 μmol/mol tyrosine. After log transformation of 3-chlorotyrosine 192 values, levels differed significantly among the groups (P=0.01; 1-way ANOVA). Levels were significantly higher (Fisher LSD test) in subjects with CAD (64±20 μmol/mol tyrosine; P=0.02) and ACS (71±36 μmol/mol tyrosine; P=0.004) than in the control subjects. However, the difference between the CAD and ACS levels was not significant.
We quantified the levels of oxidation of all 3 methionine residues in apoA-I (Online Figure IV) . However, we focused on Met(O) 148 because oxidation of that residue strongly associates with impaired ABCA1-mediated cholesterol efflux activity and reduced ability to activate lecithin-cholesterol acyltransferase. 25, 26 Importantly, preliminary studies indicated that methionine 148 was resistant to ex vivo oxidation (Methods in the Online Data Supplement; Online Figures  I and II) . In the control group, the average level of Met(O) 148 was 75±13 mmol/mol methionine ( Figure 1C ). After log transformation of Met(O) 148 values, levels were significantly higher in the subjects with CAD (120±69 mmol/mol methionine; P=0.002) and ACS (110±62 mmol/mol methionine; P=0.02) than in the control subjects.
Studies in myeloperoxidase-deficient mice strongly suggest that myeloperoxidase is the only generator of 3-chlorotyrosine during acute inflammation. 38 In contrast, other oxidative N-apoA-I as internal standard, HDL was subjected to proteolytic digestion. Peptide digests were analyzed by tandem mass spectrometry with selected reaction monitoring. Values for chloroTyr192 and Met(O) 148 were logarithmically transformed to achieve a normal distribution.
pathways can produce Met(O). 21 To determine whether myeloperoxidase might be an important pathway for promoting methionine oxidation in humans, we assessed the relationship between 3-chlorotyrosine 192 levels and Met(O) 148 levels ( Figure 1D ) in all the subjects (n=60). Linear regression analysis demonstrated a strong correlation (Pearson r=0.57; P<0.0001). The levels of 3-chlorotyrosine 192 also correlated with the levels of Met(O) 86 (r=0.52; P<0.0001; Online Figure IVD ) and Met(O) 112 (r=0.58; P<0.0001; Online Figure IVE ). Our observations suggest that myeloperoxidase contributes to methionine oxidation in vivo in human apoA-I.
We also assessed the relationship between plasma myeloperoxidase levels and levels of 3-chlorotyrosine 192 and oxidized methionine residues in HDL (Online Figure V) . Linear regression analysis revealed that myeloperoxidase levels were modestly correlated with levels of 3-chlorotyrosine 192 (r=0.34; P=0.008) but failed to correlate with levels of Met(O) 148 (r=0.24; P=0.06). Supplementation of plasma with 10 mmol/L azide, a potent inhibitor of myeloperoxidase, had no effect on methionine oxidation or tyrosine chlorination (Online Figures  II and III) . These observations suggest that myeloperoxidase in plasma has little influence on HDL oxidation.
Correlations of 3-Chlorotyrosine 192 and Met(O) 148 With Traditional CAD Risk Factors
We examined the relationship between 3-chlorotyrosine 192 levels in HDL and traditional CAD risk factors in this cohort of control and high-risk patients (Figure 2 ). Levels of 3-chlorotyrosine 192 did not associate with sex or hypertension; they also failed to correlate with total cholesterol, non−HDL-C, age, or triglycerides (data not shown). However, they were significantly related to smoking status (53.4 versus 70.6 mol/mol; nonsmoker versus smoker; P=0.007; 2-tailed Student t test) and diabetes mellitus (56.4 versus 83.2 mol/mol; nondiabetic versus diabetic subjects; P=0.001). Levels of 3-chlorotyrosine 192 correlated inversely with HDL-C levels (r=−0.27; P=0.03; Figure 2A ) but not with LDL-C levels (r=−0.13; P=0.31; Figure 2B ). Levels of 3-chlorotyrosine 192 also correlated modestly with levels of hs-CRP (r=0.38; P=0.003; Figure 2C ).
We next examined the relationship between Met(O) 148 levels and traditional CAD risk factors. Sex, age, hypertension, smoking status, total cholesterol, non−HDL-C, and triglyceride did not associate with levels of Met(O) 148. However, Met(O) 148 associated significantly with diabetes mellitus (92 versus 138 mmol/mol methionine; nondiabetic versus diabetic subjects; P=0.01). Unlike 3-chlorotyrosine 192, Met(O) 148 was not correlated with HDL-C (r=−0.23; P=0.08; Figure 2D ) but inversely correlated with LDL-C (r=−0.27; P=0.04; Figure 2E ). The correlation between Met(O) 148 and hs-CRP was not significant (r=0.08; P=0.49; Figure 2F ).
Cholesterol Efflux Capacity of Serum HDL With the ABCA1 Pathway Is Impaired in Subjects With CAD and ACS
We assessed the capacity of serum HDL to promote cholesterol efflux by the ABCA1 pathway with baby hamster kidney cells expressing or not expressing mifepristone-inducible human ABCA1. Analysis by 1-way ANOVA indicated that serum HDL efflux capacity differed among the groups (P=0.0004).
Serum HDL of subjects with CAD and ACS had significantly less cholesterol efflux capacity (10.8% and 10.0% sterol efflux; P=0.02 and <0.0001, respectively; Fisher LSD test) than that of control subjects (11.8% sterol efflux) when cells expressing ABCA1 were cholesterol donors ( Figure 3A ). There was a trend toward greater impairment of sterol efflux from ABCA1-expressing cells to serum HDL of subjects with ACS than subjects with CAD (P=0.06).
Levels of 3-Chlorotyrosine 192 and Met(O) 148 Inversely Correlate With Serum HDL's ABCA1 Cholesterol Efflux Capacity
We investigated the relationship between levels of oxidized residues in apoA-I and the cholesterol efflux capacity of serum HDL using cells that expressed ABCA1. Linear regression analysis of all the subjects (n=60) revealed an inverse correlation with levels of both 3-chlorotyrosine 192 (r=−0.33; P=0.01; Figure 3B ) and Met(O) 148 (r=−0.32; P=0.01; Figure 3C ). The cholesterol efflux capacity of serum HDL Figure VI) .
To investigate the potential contribution of methionine oxidation in vivo to impaired sterol efflux, we exposed isolated HDL to low levels of HOCl. When 29% of methionine 148 of apoA-I was converted to Met(O) 148, we observed ≈30% loss of cholesterol efflux by the ABCA1 pathway (Figure 4) . Met(O) 148 was almost completely reduced back to native methionine when oxidized HDL was incubated with pilB, a Met(O) reductase that reduces both epimers of Met(O). 39 Reduction of Met(O) to methionine completely restored the efflux capacity of HOCl-oxidized HDL (Figure 4) . The efflux capacity of control HDL, which contained ≈9% Met(O) 148, was also increased by incubation with pilB. Collectively, these observations provide strong evidence that the levels of Met(O) observed in HDL isolated from subjects with CAD are likely high enough to contribute to impaired sterol efflux by the ABCA1 pathway. Serum HDL's cholesterol efflux capability with macrophages associates with both HDL-C levels 30 and the functionality of HDL particles. 40 We, therefore, determined the relationship between HDL-C levels and the ABCA1 activity of serum HDL for all of the subjects (n=60) using linear regression analysis ( Figure 5A ). Efflux capacity correlated with HDL-C levels (P=0.02) and accounted for approximately the same variance in the data (r=0.31) as was observed for apoA-I chlorination (r=−0.33). Thus, the impaired cholesterol efflux in the CAD and ACS groups likely reflects in part lower HDL-C levels. After we controlled for HDL-C level, logistic regression analysis revealed that the inverse correlations between 3-chlorotyrosine 192 or Met(O) 148 with efflux capacity remained significant (r=−0.27; P=0.04 and r=−0.27; P=0.04, respectively). Therefore, modification of apoA-I by myeloperoxidase correlated with impaired HDL-C efflux capacity via the ABCA1 pathway, even after adjusting for HDL-C levels. In contrast, we observed no correlation of the efflux capacity of serum HDL with plasma levels of myeloperoxidase (r=−0.07; P=0.60; Figure 3D ).
We also examined the relationship between ABCA1 cholesterol efflux capacity and traditional risk factors for atherosclerosis in our subjects ( Figure 5 ). Cholesterol efflux correlated weakly with HDL-C (r=0.31; P=0.02; Figure 5A ), consistent with the observation that lipid-free or poorly lipidated apolipoproteins are the major ligands for ABCA1. 6 Efflux capacity also correlated with LDL-C (r=0.26; P=0.04; Figure 5B ), but adjusting for HDL-C levels attenuated that relationship (r=0.24; P=0.07). Cholesterol efflux did not correlate with triglyceride levels (r=0.17; P=0.19; Figure 5C ). However, after we controlled for HDL-C levels, that relationship became significant (r=0.49; P=0.0001). Efflux did not associate with sex or hypertension. Efflux did not correlate with age or total cholesterol. However, it related significantly to diabetes mellitus (11.2% versus 10.0%; nondiabetic versus diabetic subjects; P=0.01; 2-tailed Student t test). Efflux associated with smoking status (11.3% versus 10.6%; nonsmoker versus smoker; P=0.047); it also correlated with hs-CRP levels (r=−0.35; P=0.006; Figure 5D ).
3-Chlorotyrosine 192, Met(O) 148, and Efflux Capacity Associate With CVD Status
We investigated the relationships among apoA-I oxidation, ABCA1 efflux capacity, traditional cardiovascular risk factors, and CVD status ( Figure 6 ). To increase power, and because the levels of oxidized amino acids and sterol efflux capacity of HDL were similar in subjects with CAD and ACS, we included both subjects with CAD and ACS in the CVD group.
Compared with control subjects, subjects with CVD had significantly lower levels of HDL-C (mean values for case and control subjects, 45 and 61 mg/dL, respectively; P=0.0003). Cholesterol efflux capacity of serum HDL was significantly lower in CVD subjects compared with control subjects (mean values for case and control subjects, 10.4% and 11.8%, respectively; P=0.001). Increased efflux capacity by the ABCA1 pathway associated with a decreased risk of CVD (odds ratio per 1 SD change, 0.30; 95% confidence interval, 0.14-0.66; P=0.003). This association remained robust after adjusting for HDL-C levels (adjusted odds ratio, 0.33; 95% confidence interval, 0.15-0.76; P=0.009). Elevated levels of 3-chlorotyrosine 192 and Met(O) 148 of apoA-I in HDL were also highly significantly associated with CVD status (odds ratios, 4.1 and 7.3; P=0.008 and 0.006, respectively). In contrast, plasma levels of myeloperoxidase and LDL-C were not associated with CVD status (Figure 6 ).
Discussion
Understanding the pathways that impair sterol efflux by HDL may lead to new diagnostic and therapeutic approaches to atherosclerosis. In this study, we found that levels of 3-chlorotyrosine 192 and Met(O) 148 were significantly higher in apoA-I of HDL isolated from subjects with CAD or ACS than in HDL from apparently healthy control subjects. We also found that serum HDL of subjects with CAD and ACS was significantly less able to promote cellular sterol efflux by the ABCA1 pathway. There was a strong inverse association between ABCA1 efflux capacity with CVD status, and this association persisted after adjustment for HDL-C. Levels of 3-chlorotyrosine 192 and Met(O) 148 positively associated with CVD status. Moreover, serum HDL's ability to promote sterol efflux by the ABCA1 pathway correlated inversely with levels of 3-chlorotyrosine 192 and Met(O) 148. Because chlorination of tyrosine 192 in concert with oxidation of methionine residues in vitro impairs the ABCA1 activity of apoA-I, 23, 25 and 3-chlorotyrosine is a characteristic chemical fingerprint of myeloperoxidase, 38 our observations suggest that myeloperoxidase contributes to the generation of dysfunctional HDL with impaired ABCA1 efflux capacity in humans with atherosclerotic vascular disease.
A key issue is whether the levels of oxidized apoA-I we detected in apoA-I of HDL of subjects with CAD and ACS were high enough to potentially reduce HDL's sterol efflux capacity. When HDL oxidized in vitro with HOCl contained levels of Met(O) similar to those observed in vivo, its ability to promote sterol efflux by the ABCA1 pathway was significantly impaired. Importantly, the ability of oxidized HDL to promote sterol efflux by the ABCA1 pathway was completely restored when Met(O) was converted to methionine by Met(O) reductase. In contrast, the levels of 3-chlorotyrosine we detected in HDL were low and unlikely to contribute directly to impaired sterol efflux capacity by the ABCA1 pathway. Collectively, these observations provide strong evidence that the levels of Met(O) observed in HDL isolated from subjects with CAD likely impair sterol efflux. In future studies, it will be important to determine whether other modifications of apoA-I, such as lipid adduction 32 and tryptophan oxidation, 41 contribute to impaired sterol efflux by the ABCA1 pathway.
Although methionine can be oxidized by lipid hydroperoxides in HDL as well as other pathways, 42, 43 the correlation between levels of Met(O) 148 and levels of 3-chlorotyrosine 192 (a unique product of myeloperoxidase) 38 indicates that myeloperoxidase likely contributes to the oxidation of methionine residues in vivo. In contrast to our observations with the ABCA1 pathway and lecithin-cholesterol acyltransferase activation, 25, 26 the oxidation of methionine residues in apoA-I does not impair sterol efflux from human monocyte-derived macrophages. 36 However, the contribution of the ABCA1 pathway to efflux in these cells is uncertain, and the clinical relevance of these observations is unclear, because there is no evidence that impaired efflux with human macrophages associates with CVD status. In a secondary analysis, we also found that levels of 3-chlorotyrosine 192 and Met(O) 148 associated with smoking and diabetes mellitus status. Indeed, increased levels of oxidized methionine residues in apoA-I of isolated HDL were observed in a study of subjects with type 1 diabetes mellitus. 44 In future studies, it will be of interest to determine whether smoking and diabetes mellitus-2 major risk factors for CAD-associate with impaired sterol efflux capacity and HDL modification by myeloperoxidase.
There was a strong trend (P=0.06) toward greater impairment of serum HDL's efflux capacity with the ABCA1 pathway in subjects with ACS than in subjects with CAD. However, the 2 groups contained similar levels of 3-chlorotyrosine and Met(O) in their HDLs. These observations suggest that additional factors impair sterol efflux in subjects with ACS. One important contributor may be acute inflammation, [12] [13] [14] 45 a prominent component of unstable angina and acute myocardial infarction. 45 Consistent with this suggestion, we observed a significant, inverse correlation between hs-CRP levels and the sterol efflux capacity of serum HDL in our cohort. Acute inflammation alters the concentration of HDL-associated enzymes and remodels the human HDL proteome, 46 and animal models and human studies provide strong support for the hypothesis that inflammation converts HDL into a dysfunctional form. [12] [13] [14] 28, 47 Cholesterol efflux to HDL may be one important target because lipopolysaccharide, a potent inducer of acute inflammation, impairs cholesterol efflux from macrophages in mice. 13 Our detection of higher levels of 3-chlorotyrosine 192 and Met(O) 148 in plasma HDL from subjects with CAD and ACS might seem surprising, given that blood is richly endowed with antioxidants that scavenge HOCl. Moreover, levels of the oxidized residues were similar in the 2 groups, suggesting that acute inflammation is unlikely to promote oxidation of circulating HDL. Thus, the oxidized HDL in plasma might be generated elsewhere, perhaps in a microenvironment that is depleted of antioxidants but enriched in macrophages, myeloperoxidase, and HOCl. 17 Many lines of evidence indicate that atherosclerotic lesions provide such a milieu. 17 One intriguing possibility is that HDL is oxidized in atherosclerotic lesions (or other inflamed tissues rich in leukocytes), 45 resulting in a feedback loop in which reduced sterol efflux prompts macrophages to become foam cells, accelerating atherosclerosis. In turn, these events promote additional HDL oxidation and the appearance of myeloperoxidase-oxidized HDL in blood. Regardless of whether it originates in blood or lesions, however, 3-chlorotyrosine and Met(O) in circulating HDL might be a useful indicator of the risk of CVD and the efficacy of antioxidant interventions.
The levels of chlorotyrosine 192 and Met(O) 148 were similar in patients with ACS and stable CAD, raising the possibility that the subjects with ACS had elevated levels of the 2 oxidized amino acids before they developed clinical symptoms. In future studies, it will be of great interest to determine whether levels of myeloperoxidase-oxidized HDL can identify apparently healthy subjects who are at increased risk of CAD, and whether HDL oxidation is enhanced in conditions that predispose humans to clinically significant atherosclerosis.
